Careers
Contact Us
Who We Are
Who We Are
Our History
Mission & Values
Our Team
Leadership
Board of Directors
Careers
ARCUS Genome Editing
Scientific Publications
ARCUS Platform
In Vivo Gene Editing
Pipeline
In Vivo
Gene Editing
Investors
Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Sustainability
Investor FAQs
Partnering
Uncategorized
Uncategorized
Uncategorized
CAR T Explainer
Read More
Uncategorized
ASH Poster 2019
Read More
Uncategorized
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
Read More
Uncategorized
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
Read More
Uncategorized
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
Read More
Uncategorized
Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations
Read More
Uncategorized
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress
Read More
Uncategorized
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
Read More
Uncategorized
Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress
Read More
Uncategorized
Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
Read More
Uncategorized
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
Read More
Uncategorized
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
Read More
Uncategorized
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Read More
Uncategorized
Elo Life Systems Announces a Collaboration With Ashland Subsidiary Avoca to Scale a Sustainable, Key Input for Fragrances
Read More
Uncategorized
Science Article About the Quest to Cure HBV Brings Context to Precision BioSciences Collaboration With Gilead
Read More
1
2